22 completed, 4 unknown, 2 terminated. 10 Phase 2, 8 Phase 4, 3 Not applicable, 3 Phase 1, 2 Phase 3.
Follow this drug Literature Review of Selegiline trials Research Report on Selegiline
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Determine the Bioavailability of Selegiline TDS 6mg/24 Hours vs EMSAM in Healthy Subjects Pharmacokinetic profiles of Selegiline TDS and EMSAM - MDD | Completed | Corium Innovations, Inc. | 12 | 2025-02-10 | 2026-02-25 | |
| Pharmacokinetic Profile of Betahistine With and Without Selegiline in Healthy Volunteers Betahistine dihydrochloride, Selegiline-hydrochloride - Ménière's Disease | Phase 1 | Completed | Ludwig-Maximilians - University of Munich | 15 | 2021-06-02 | 2023-07-12 |
| Clinical Trial of Selegiline Plus Docetaxel for the Treatment of Metastatic, Castrate-resistant Prostate Adenocarcinoma Selegiline, Docetaxel - Metastatic Castration-resistant Prostate Cancer, Adenocarcinoma of the Prostate | Phase 2 | Unknown | László Mangel | 110 | 2020-05-18 | 2020-10-14 |
| Selegiline for the Treatment of Excessive Daytime Sleepiness in Parkinson's Disease Selegiline - Parkinson Disease | Phase 4 | Completed | Second Affiliated Hospital of Soochow University | 141 | 2020-03-01 | 2021-05-07 |
| Selegiline and Reward Processing Selegiline Hydrochloride 10 MG, Placebo - Healthy | Not applicable | Unknown | University of Oxford | 54 | 2019-09-18 | 2019-10-17 |
| Sagene 2014 - Parkinson's Disease and Erectile Dysfunction Selegiline, Tadalafil - Parkinson's Disease, Erectile Dysfunction | Phase 4 | Unknown | University of South Florida | 10 | 2014-09-01 | 2017-12-20 |
| Clinical Research Study to Evaluate Selegiline in the Treatment of Borderline Personality Disorder Selegiline, Placebo (for Selegiline) - Borderline Personality Disorder | Phase 3 | Completed | Mood and Anxiety Research, Inc | 30 | 2012-10-01 | 2015-10-08 |
| Combined Donepezil and Selegiline Effects on Cocaine-Reinforced Behavior High-dose donepezil, Low-dose donepezil, Selegiline - Cocaine Use Disorders | Phase 2 | Completed | Midwest Biomedical Research | 12 | 2012-02-01 | 2013-12-18 |
| Testing a Full Substitution Therapy Approach As Treatment of Tobacco Dependence Selegiline + nicotine replacement therapy, placebo + nicotine replacement therapy - Nicotine Dependence | Not applicable | Terminated | Centre for Addiction and Mental Health | 40 | 2007-07-01 | 2013-08-29 |
| Phase IV:Safety and Efficacy of EMSAM in Adolescents With Major Depression Selegiline Transdermal System, Placebo - Major Depressive Disorder | Phase 4 | Completed | Somerset Pharmaceuticals | 308 | 2007-07-01 | 2014-01-15 |
| Efficacy of Selegiline in Negative Symptoms of Schizophrenia Selegiline - Schizophrenia | Early Phase 1 | Completed | Tabriz University | 70 | 2007-04-01 | 2008-07-23 |
| PK Comparison of 6mg and 12mg EMSAM in Elderly vs. Non-Elderly EMSAM (Selegiline Transdermal System) 6mg, EMSAM (Selegiline Transdermal System) 12mg - Healthy | Phase 4 | Completed | Somerset Pharmaceuticals | 32 | 2007-04-01 | 2007-09-19 |
| Evaluation of Adhesion and Dermal Tolerability of EMSAM EMSAM (Selegiline Transdermal System) 6mg/24Hr, EMSAM (Selegiline Transdermal System) 9mg/24Hr, EMSAM (Selegiline Transdermal System) 12mg/24hr - Healthy | Phase 4 | Completed | Somerset Pharmaceuticals | 300 | 2007-04-01 | 2007-09-19 |
| A Pilot Study Assessing EmSam in Bipolar Depression EmSam - Bipolar Depression | Phase 4 | Terminated | New York State Psychiatric Institute | 3 | 2007-03-01 | 2014-10-28 |
| Efficacy of Orally Disintegrating Selegiline in Parkinson's Patients Experiencing Adverse Effects With Dopamine Agonists orally disintegrating selegiline (Zelapar) - Parkinson's Disease | Phase 4 | Completed | Parkinson's Disease and Movement Disorder Center of Boca Raton | 77 | 2007-03-01 | 2014-10-31 |
| Selegiline to Zelapar Switch Study in Parkinson Disease Patients Zelapar - Parkinson's Disease | Phase 4 | Completed | Baylor College of Medicine | 48 | 2007-01-01 | 2023-08-09 |
| Selegiline Patch for Treatment of Nicotine Dependence Selegiline, matching placebo - Tobacco Use Disorder | Phase 2 | Completed | Stanford University | 243 | 2005-07-01 | 2016-08-10 |
| Effectiveness of Selegiline in Treating Marijuana Dependent Individuals - 1 Selegiline hydrochloride, Placebo - Marijuana Abuse | Phase 2 | Completed | National Institute on Drug Abuse (NIDA) | 19 | 2005-03-01 | 2017-01-12 |
| Usefulness of Selegiline as an Aid to Quit Smoking - 1 Selegiline, Placebo - Tobacco Use Cessation | Phase 2 | Completed | Yale University | 101 | 2004-07-01 | 2015-03-31 |
| Assessment of Potential Interactions Between Methamphetamine and Selegiline - 1 Selegiline - Amphetamine-Related Disorders | Phase 1 | Unknown | National Institute on Drug Abuse (NIDA) | 16 | 2001-09-01 | 2017-01-11 |
Showing 20 of 28. Sign in to see all of them.
Cocaine-Related Disorders (5) · Parkinson Disease (4) · Cognitive Dysfunction (3) · Depression (3) · HIV Infections (3) · AIDS Dementia Complex (2) · Cognition Disorders (2) · Tobacco Use Disorder (2) · AIDS-Related Complex (1) · Acquired Immunodeficiency Syndrome (1) · Amphetamine-Related Disorders (1) · Anxiety Disorders (1) · Bipolar Disorder (1) · Borderline Personality Disorder (1) · Brain Injuries (1)
National Institute on Drug Abuse (NIDA) (6) · Somerset Pharmaceuticals (3) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · Baylor College of Medicine (1) · Centre for Addiction and Mental Health (1) · Corium Innovations, Inc. (1) · Ludwig-Maximilians - University of Munich (1) · László Mangel (1) · Midwest Biomedical Research (1) · Mood and Anxiety Research, Inc (1) · New York State Psychiatric Institute (1) · Parkinson's Disease and Movement Disorder Center of Boca Raton (1) · Second Affiliated Hospital of Soochow University (1) · Stanford University (1) · Tabriz University (1)
United States (21) · Canada (1) · China (1) · Germany (1) · Hungary (1) · Iran (1) · Malaysia (1) · United Kingdom (1)
Walter Ling, M.D. (2) · Ahmed Elkashef, MD (1) · Bernard Le Foll, MD, PhD (1) · Bradford Navia (1) · Brent A Moore, Ph.D. (1) · Catherine Harmer, PhD (1) · Chun-feng Liu, MD,PhD (1) · David Simpson, M.D. (1) · Deborah Deliyannides, M.D. (1) · Fatemeh Ranjbar Kouchaksaraei, Assistant Professor (1) · George Bigelow, Ph.D. (1) · Giovanni Schifitto (1) · Giovanni Schifitto, M.D. (1) · Greg Kricorian, MD (1) · James Cornish, M.D. (1)
PMID 37230961, PMID 16730924, PMID 18042509, PMID 19855267, PMID 19890073, PMID 19939587, PMID 20707784, PMID 21181521, PMID 36375174, PMID 37920833, PMID 40932155, PMID 41938228
2019 (1), R01DA012268 (1), R01DA015757 (1), R01DA017457 (1), R21DA029787 (1)